Posts on JNJ

Latest ideas and analyses related to Johnson & Johnson Common Stock

You may also enter '* TRADES' to see all trade recommendations, '* QUESTIONS' to see all questions, and '* COMMENTS' to see all comments.
JNJ

+33 pts



$JNJ Pharma delivering, but macro likely to impact 2023

By realmomobags on July 20, 2022, 5:20 a.m.
Tagged topics: earnings results

Views: 11, Votes: 4, Responses: 0, Attachments: 1
MRK , PFE , JNJ , SNY , GSK , ARVN , BPMC , INCY , MRTX , SGEN , ARGX , ARQT , VRTX , GILD , BIIB

+45 pts



Global Healthcare: Pharmaceuticals Framing the 2022 M&A landscape for biopharma

By ethonomics on April 14, 2022, 12:11 p.m.
Tagged topics: deep dive , mergers and acquisitions

Views: 67, Votes: 8, Responses: 0, Attachments: 1
AJG , BRO , DUK , EVGR , JNJ , LNT , PG , WMT , UNH , XEL , ADI , AMAT , CCL , LEN , LRCX , MCHP , MU , NXPI , PHM , QRVO , TXN , UAL

+34 pts



Technical Analysis: Inflection Points Risk-Off Rate Rise Remains Relevant

By rIsILAwr on April 11, 2022, 9:04 a.m.
Tagged topics: technical analysis

Views: 43, Votes: 3, Responses: 0, Attachments: 1
JNJ

+87 pts



$JNJ : Intra-Qtr Q4 Trends Confirm Upside for JNJ’s U.S. Pharma Business; Reiterate Outperform and $200 Target Price

By KHUN on Dec. 30, 2021, 6:25 a.m.
Tagged topics: analyst checks , analyst upgrade , analyst raises target

Views: 102, Votes: 4, Responses: 0, Attachments: 0
JNJ

+35 pts



Johnson & Johnson (JNJ) in HOLT: Shaking up the Portfolio

By KHUN on Nov. 23, 2021, 11:31 p.m.
Tagged topics: valuations , analyst checks , quantitative easing

Views: 53, Votes: 4, Responses: 0, Attachments: 1
JNJ

+32 pts



$JNJ Expects Sequential Recovery in Med Devices and Key End Mkts in Q4 & 2022; Raises Guidance Accordingly; Reiterate Outperform

By KHUN on Oct. 22, 2021, 7:50 p.m.
Tagged topics: analyst checks , analyst raises target , upside to estimates

Views: 49, Votes: 2, Responses: 0, Attachments: 2
JNJ

+31 pts



$JNJ - Morgan Stanley anticipates strong performance across all 3 business segments, views it as a high-quality GARP stock (deep dive)

By phenphen on May 31, 2021, 10:23 a.m.
Tagged topics: discount valuation , deep dive , GARP , Morgan Stanley , healthtech

Views: 264, Votes: 1, Responses: 0, Attachments: 31
PFE , JNJ , AZN

+33 pts



$PFE - Goldman sees further upside to consensus estimates partly driven by safety concerns related to $JNJ and $AZN COVID vaccines

By phenphen on May 4, 2021, 1:37 p.m.
Tagged topics: booster vaccine , Goldman Sachs , upside to estimates , healthtech , covid vaccines , vaccine hesitancy , safety concerns , Prevnar vaccine

Views: 200, Votes: 1, Responses: 1, Attachments: 5
PFE , JNJ

+60 pts



$PFE - Goldman says in-vitro COVID vaccine data for Brazil strain looks encouraging

By phenphen on March 9, 2021, 9:59 a.m.
Tagged topics: analyst checks , COVID-19 , vaccine , Goldman Sachs , Brazil strain , virus mutations

Views: 181, Votes: 1, Responses: 0, Attachments: 3
MRNA , JNJ , PFE , BNTX , MRK , GILD , REGN , AZN

+31 pts



Goldman outlines key dates for COVID vaccine updates, which could help stocks...looks like a busy fall season

By mooreideas on Aug. 12, 2020, 10:42 a.m.
Tagged topics: positive catalyst , COVID-19 , vaccine

Views: 131, Votes: 1, Responses: 0, Attachments: 9